Recurrent Solid Tumor Clinical Trials

4 recruiting

Recurrent Solid Tumor Trials at a Glance

9 actively recruiting trials for recurrent solid tumor are listed on ClinicalTrialsFinder across 6 cities in 11 countries. The largest study group is Phase 1 with 6 trials, with the heaviest enrollment activity in New York, Houston, and Barcelona. Lead sponsors running recurrent solid tumor studies include Eli Lilly and Company, Genentech, Inc., and Bayer.

Browse recurrent solid tumor trials by phase

Treatments under study

About Recurrent Solid Tumor Clinical Trials

Looking for clinical trials for Recurrent Solid Tumor? There are currently 4 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Recurrent Solid Tumor trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Recurrent Solid Tumor clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 19 of 9 trials

Recruiting
Phase 1

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

Advanced Solid TumorMetastatic Solid TumorRecurrent Solid Tumor+1 more
Eli Lilly and Company420 enrolled31 locationsNCT06465069
Recruiting

NTRK Gene Fusion - Positive Advanced or Recurrent Solid Tumors, a Rare Cancer Caused by Specific Changes in the Genes

Advanced or Recurrent Solid Tumor Harboring an NTRK Gene Fusion
Bayer100 enrolled1 locationNCT04945330
Recruiting
Phase 1Phase 2

Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma

Recurrent Malignant Solid NeoplasmRefractory Malignant Solid NeoplasmRecurrent Solid Tumor+19 more
St. Jude Children's Research Hospital90 enrolled10 locationsNCT04901702
Recruiting
Phase 1

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

Metastatic Solid TumorsLocally Advanced Solid TumorsRecurrent Solid Tumors
Genentech, Inc.250 enrolled18 locationsNCT06031441
Recruiting
Phase 1

A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors

Advanced Solid TumorMetastatic Solid TumorRecurrent Solid Tumor+1 more
Eli Lilly and Company490 enrolled28 locationsNCT06238479
Recruiting

Special Drug Use-results Surveillance of Tafinlar/Mekinist

BRAF V600E Mutation-positive Unresectable Advanced or Recurrent Solid Tumor
Novartis Pharmaceuticals110 enrolled68 locationsNCT06262919
Recruiting
Phase 1Phase 2

A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer

Metastatic CancerSolid TumorUnresectable Solid Tumor+3 more
Spago Nanomedical AB90 enrolled2 locationsNCT06184035
Recruiting
Phase 2

NCCH2006/MK010 Trial (FORTUNE Trial)

FGFR Gene AlterationsAdvanced or Recurrent Solid Tumors
National Cancer Center, Japan75 enrolled7 locationsNCT04962867
Recruiting
Phase 1

EVM16 Injection As a Single and Combination with Tislelizumab in Solid Tumors

Advanced or Recurrent Solid Tumors
Peking University78 enrolled2 locationsNCT06541639